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Abstract 
Background: Chronic obstructive pulmonary disease (COPD) is an irreversible disease, diagnosed predominantly in 
smokers. COPD is currently the third leading cause of death worldwide. Far more than 15 % of smokers get COPD: in 
fact, most develop some amount of pulmonary impairment. Smoking‑related COPD is associated with both acute 
exacerbations and is closely correlated to comorbidities, such as cardiovascular disease and lung cancer. The objective 
of our study (KOL‑Örestad) is to identify biomarkers in smokers and ex‑smokers, with early signs of COPD, and com‑
pare these biomarkers with those of non‑smokers and healthy smokers/ex‑smokers. The participants in the study are 
recruited from Örestadskliniken, a primary health care clinic in Malmö, Sweden.
Methods: Two hundred smokers and ex‑smokers diagnosed with COPD with airflow restriction according to GOLD 
stages 1–4 will be included and compared with 50 healthy never‑smokers, and 50 healthy smokers/ex‑smokers with‑
out airflow restriction (total n = 300). The age distribution is 35–80 years. The participants undergo a health examina‑
tion including medical history, smoking history, lung function measurements, and respond to a “Quality of Life” ques‑
tionnaire. Blood samples are drawn every 6 months during a period of 5 years. Additional blood sample collection is 
performed if participants are experiencing an exacerbation. The blood fractions will be analyzed by standard clinical 
chemistry assays and by proteomics utilizing mass spectrometry platforms. Optimal sample integrity is ensured by 
rapid handling with robotic biobank processing followed by storage at −80 °C. The study has been approved by the 
Regional Ethical Review Board in Lund (http://epn.se/en), (Approval number: DNR 2013/480), and registered at the 
NIH clinical trial registry (http://clinicaltrials.gov).
Results and discussion: Currently, 220 subjects are enrolled in the study.
Conclusions and future directions: The study design will enable discovery of new biomarkers by using novel 
mass spectrometric techniques that define early changes of COPD. Such panels of novel biomarkers may be able to 
distinguish COPD from closely related diseases, co‑morbidities, and contribute to an increased understanding of these 
diseases. 
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Background
Chronic obstructive pulmonary disease (COPD) is an 
irreversible disease, diagnosed predominantly in smok-
ers. COPD is currently the third leading cause of death 
worldwide [1, 2]. It is a heterogeneous inflammatory 
disease characterized by different phenotypes, such as 
airflow limitation that is not fully reversible, chronic 
sputum production (chronic bronchitis) and destruc-
tion of parenchymal lung tissue (emphysema) [2]. Active 
smoking is the main risk factor for developing COPD. 
Far more than 15 % of smokers get COPD: in fact, most 
develop some amount of pulmonary impairment [3]. 
Smoking-related COPD is associated with acute exacer-
bations and is closely correlated to comorbidities, such as 
cardiovascular disease and lung cancer [2, 4]. The num-
ber of inflammatory cells and mediators is increased in 
the lungs and can be detected in bronchoalveolar lav-
age, biopsies and blood [5]. The pathophysiology of these 
systemic manifestations is unclear; however, several 
attempts to study biomarkers closely associated with 
COPD phenotypes have been performed, both in cross-
sectional and longitudinal studies. Standardized meth-
odology and strict quality control, replication of data 
in different cohorts, as well as robust and cost-effective 
clinical tests are needed [6]. Significant differences in 
biomarkers when comparing patients with COPD with 
former or non-smoking controls have been described 
[7]. Some biomarkers showed large variability within 
the three  months study period. Plasma fibrinogen was 
the most ‘reliable’ analyte and was elevated, along with 
plasma CRP, in COPD patients experiencing exacerba-
tions compared to COPD patients without exacerbations.
However, expiratory volume in one second (FEV1) is 
the most widely used parameter to evaluate the disease 
severity with increasing airflow limitations [2, 8]. The 
ratio of FEV1 to forced vital capacity (FVC) is measured 
with spirometry and is currently most frequently used 
to classify the disease state of COPD according to the 
Global initiative for Obstructive Lung Disease (GOLD) 
stages 1–4 [9]. Yet, FEV1 correlates poorly to clinical 
symptoms in early stages of COPD, but slightly better in 
later stages of the disease [2]. A study from Evaluation of 
COPD Longitudinally to Identify Predictive Surrogate 
Endpoints (ECLIPSE) found that the degree of airflow 
limitation does not reflect the heterogeneity of COPD. 
Additionally, a substantial part of the COPD patients, 
even with severe airflow obstruction, did not complain 
of any symptoms [10]. Furthermore, there are recent sug-
gestions to classify structural changes in COPD using 
CT-imaging of morphological changes in pulmonary 
tissue tracts [11]. The most recent GOLD classification 
includes both symptoms and “Quality of Life” (QoL) in 
addition to lung function [12].
COPDGene is another front line study that was first to 
define both genetic factors implicated in COPD, as well 
as to investigate structural pulmonary changes with CT. 
The original cross-sectional study, which started 2008, 
has been extended with several follow-up studies to 
detect changes during disease progression [13].
Over the last decade, several studies have attempted to 
identify new biomarkers of COPD in blood, biomarkers 
both for diagnosing the disease as well as to predict exacer-
bations and to classify disease states [14, 15]. A number of 
studies on COPD plasma samples analyzed by mass spec-
trometry reported candidate protein biomarkers [16–18]. 
However, the current COPD studies available on patient 
blood samples analyzed by mass spectrometry are limited 
and there is still a lack of reliable biomarkers, a fact that 
complicates personalizing the care of patients with COPD.
The objective of this study (KOL-Örestad) is to identify 
circulating biomarkers in smokers and former smokers 
with early signs of COPD and compare these biomark-
ers with those of non-smokers and healthy smokers/
ex-smokers. This could facilitate early diagnosis, evalua-
tion of treatment outcome and more accurately classify 
patients with COPD. Participants are recruited from 
Örestadskliniken, a primary health care clinic in Malmö, 
Sweden. KOL-Örestad is the first COPD study to com-
bine a primary health care, with a centralized large scale 
state hospital in a collaborative effort with academia.
Methods
Study outline
This study is a close collaboration between a primary 
health care clinic (Örestadskliniken) in Malmö, the Skåne 
University Hospital in Malmö and Lund, and the Centre 
of Excellence in Biological and Medical Mass Spectrom-
etry (CEBMMS, http://cebmms.lu.se) at Lund University, 
as depicted in Fig. 1, where the infrastructure of the study 
is illustrated. The study was initiated in 2014 and will 
continue for five  years. The collaboration provides effi-
cient blood sample access and high quality samples. The 
study has been approved by the Regional Ethical Review 
Board in Lund (http://epn.se/en), (Approval number: 
DNR 2013/480), and registered at the NIH clinical trial 
registry (http://clinicaltrials.gov).
Blood biomarkers from two hundred smokers and ex-
smokers with diagnosed COPD according to GOLD stage 
1–4 will be compared to those of a control group of 50 
healthy never-smokers and 50 healthy smokers/ex-smok-
ers (Table  1). Exclusion criteria include presence of a 
chronic inflammatory disease or treatment with steroids 
or any other immunomodulatory treatment that is unre-
lated to exacerbations of COPD. These conditions may 
otherwise interfere with the biomarkers measured in the 
study.
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The participants will undergo health examinations 
including heart and lung, as well as blood pressure and 
spirometry. They will also fill out a QoL questionnaire 
regarding smoking habits, COPD symptoms, disease his-
tory and current medication. Blood samples are collected 
every six months, which are processed and stored as indi-
vidual samples of plasma, buffy coat, red blood cells, serum 
and whole blood. Blood samples are collected in separate 
tubes (vacutainers) containing sodium heparin, sodium 
citrate or EDTA (ethylenediaminetetraacetic acid) as anti-
coagulants, or clot activator for serum separation. Separate 
plasma tubes are used to analyze a defined list of biomark-
ers at the Clinical Chemistry Laboratory at Skåne Univer-
sity Hospital in Malmö. Additional blood sample collection 
is performed when participants experience exacerbations.
All data are stored in a clinical database, using Research 
Electronic Data Capture (REDCap) as a data capture tool 
[19]. The blood samples will be stored at −80  °C in the 
biobank and subsequently be analyzed by liquid chroma-
tography mass spectrometry (nano LC-MS/MS) tech-
niques at CEBMMS, Lund University. The current status 
of the study recruitment and the participant distribution 
according to the GOLD standards are shown in Fig.  2. 
Currently, there are more participants in the healthy 
group and in GOLD stage 2, while participants in GOLD 
stage 4 are being recruited.
Clinical samples and biobanking
The biobanking workflow has previously been developed 
at CEBMMS for rigorous standardization for large scale 
biobanking [20–23]. The blood samples are collected at 
the primary health care clinic and transported by a cou-
rier to the biobank at CEBMMS for aliquoting and stor-
age. Four vacutainers (EDTA, citrate, heparin, serum) 
are centrifuged at 2000g for 10 min at room temperature 
in order to separate blood into three fractions: plasma, 
buffy coat and red blood cells. The automatic aliquoting 
of samples is performed by a robot (HAMILTON robot 
MicroLab Starlet, Hamilton, Bonaduz AG, Switzerland) 
that aliquots 70 μL of the sample per vial into half of the 
sample rack of a 384-well plate. Thus, blood from two 
subjects can be stored in parallel into one 384-well plate. 
The 1-D barcode on the vials arriving from the clinic are 
matched with another 1-D barcode on the 384-well plate. 
Each individual aliquot is subsequently labeled with a 2-D 
barcode encrypted for each patient and sample type to 
provide full traceability of the samples. The aliquot vials 
are then sealed with aluminum foil and punched individ-
ually. All plates are stored at −80 °C in a fully automated 
biobank storage unit (LICONIC freezer STT1k5 ULT, 
Liconic AG, Mauren, Liechtenstein) that is able to store 
clinical samples at a density of five million tubes [23]. 
This procedure, from sample collection to storage in the 
biobank, takes less than 2 h, which ensures high sample 
Fig. 1 A schematic illustration of the partners within the COPD 
study: The primary health care clinic “Örestadskliniken”, the Skåne Uni‑
versity Hospitals in Malmö and Lund “Region Skåne”, and the Centre 
of Excellence in Biological and Medical Mass Spectrometry (CEBMMS) 
at Lund University
Table 1 Study participant distribution according to the GOLD standards
The enrolled subjects will be divided in the following study groups. The total number of participants will be 300, including 50 healthy never smokers, 25 healthy 
smokers and ex-smokers, 25 at risk smokers and ex-smokers, 200 participants with GOLD stage 1–4 divided in 75 with GOLD stage 1 and 2 respectively (smokers and 
ex-smokers) and 25 with GOLD stage 3 and 4 respectively COPD participants (smokers and ex-smokers)
Study groups by pack years  
and air flow limitation




Healthy never smokers n = 50 0 No
Healthy smokers/ex‑smokers n = 25 <20 No
At risk smokers/ex‑smokers n = 25 >20 No
GOLD stage 1 smokers/ex‑smokers n = 75 >20 FEV1 ≥ 80 %
GOLD stage 2 smokers/ex‑smokers n = 75 >20 50 % ≤ FEV1 < 80 %
GOLD stage 3 smokers/ex‑smokers n = 25 >20 30 % ≤ FEV1 < 50 %
GOLD stage 4 smokers/ex‑smokers n = 25 >20 FEV1 < 30 %
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quality and safe handling of the samples. By  producing 
multiple aliquots from the same sample, the freezing-
and-thawing procedure is avoided, which may otherwise 
decrease sample quality. Each participant is assigned a 
unique identifier (Study ID) allowing all samples and data 
to be handled anonymously. The study ID can only be 
deciphered by clinicians at Örestadskliniken. For analy-
sis, the aliquot vials can be retrieved via electronic com-
mand through the computerized biobanking system.
Clinical database
The data acquired are stored in a database, KOL-Örestad 
database, including clinical patient data, blood pressure, 
spirometry, and a QoL questionnaire detailing smoking 
habits, COPD symptoms, and disease history. By use of 
the barcode or patient study ID, all clinical demograph-
ics, type of blood samples, and analyzed output data 
stored in the database, can be traced from each patient. 
REDCap from Vanderbilt University, TN, USA is selected 
as an electronic data capture tool for collection and man-
aging the study data. REDCap provides a flexible and eas-
ily programmable interface especially adapted for clinical 
studies [19]. REDCap has user-specified input modules 
for a specific cluster of variables, e.g. modules on: QoL, 
blood sampling, spirometry, without restriction in time 
and numbers. User allowance can be adjusted for differ-
ent users, e.g. clinicians and researchers. This ensures 
patient integrity and maximizes flexibility of the platform. 
All patient data that are handled outside the health care 
sector is encrypted and handled anonymously.
REDCap also functions as a planning instrument for 
clinicians, facilitating the planning of the number of 
patient follow ups each participant has completed. This 
gives the involved clinicians and researchers an excellent 
overview of all participants and their level of completion 
in the study.
Health Information System (HIS) provides the foun-
dation for decision-making and is comprised of four key 
functions: data generation, compilation, analysis and syn-
thesis, and communication and use (Fig.  3). Data from 
the health care sector is collected within HIS as well as 
analyzed and controlled for quality, relevance, and timeli-
ness [24].
Data acquisition
The blood samples will be prepared for data acquisition 
by mass spectrometry by dilution, addition of chicken 
lysozyme, solubilization, reduction, alkylation, digestion 
with trypsin, spiking with heavy labeled peptide stand-
ards and centrifugation. More details of the preparations 
will be optimized and validated for a multiple reaction 
monitoring (MRM) workflow for the potential protein 
biomarkers from the collected blood samples, which will 
be analyzed by liquid chromatography mass spectrome-
try (nano LC-MS/MS). The confirmation of protein iden-
tities will be carried out based on a library obtained from 
Fig. 2 Lung function and GOLD stages of the participants currently enrolled in the study. The y-axis represents the FEV1/FVC ratio from the spirom‑
etry test and the x-axis shows patient classification in the following groups: healthy, at risk and COPD participants GOLD stage 1–3
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Proteome database search (v 1.4, Thermo Scientific, San 
José, CA) and prior data dependent analysis (DDA) of 
pooled plasma samples from COPD patients and healthy 
participants.
The data input and logistical work flow is depicted in 
Fig. 3, followed by data output from resulting assay read-
outs. Separate blood samples will be analyzed by stand-
ard clinical chemistry assays.
Results and discussion
The aim of the study includes novel biomarker technol-
ogy development on blood collections of patients with 
COPD and additional sample collections during exacer-
bations. COPD patients who also have cardiovascular dis-
eases and lung cancer are included in the study, enabling 
cross over multi-factorial effects and co-morbidities to be 
investigated. Currently, 220 subjects are enrolled in the 
study. Because screening with spirometry is not regularly 
performed in the primary health care clinic on the aging 
population, new available tests would greatly benefit diag-
nostics. Biobanks are highly important for the introduc-
tion of personalized medicine in future health care [25, 26]. 
Preservation of clinical samples collected daily is an essen-
tial  undertaking, because each sample is unique and has 
the potential to facilitate future research and diagnostics.
Quantitative mass spectrometry provides an excellent 
method to identify biomarkers that can be used in person-
alized medicine. Mass spectrometry is very sensitive, which 
makes sample quality even more important. The present 
system generates aliquots of 70 μL in a 384-well plate using 
an automated sample processing platform. This minimizes 
the probability of methodological errors and improves sam-
ple quality by avoiding the use of previously thawed sam-
ples [23]. In our workflow, we have developed a method for 
safe handling of samples to maximize sample preservation, 
which is robust and well suited for clinical studies.
Conclusion and future directions
In this study, the disease progression will be followed 
longitudinally for each patient. Novel disease biomarkers 
identified by proteomics (significantly up- or down-reg-
ulated due to disease state) will be related to measured 
clinical parameters. The study design will enable the dis-
covery of new biomarkers that define early changes of 
COPD, distinct from markers of closely related diseases, 
such as cardiovascular disease and lung cancer. Such pan-
els of novel biomarkers can contribute to an increased 
understanding of these diseases.
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